Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
January 29, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Kidney Transplant Market Predicted to Reach $7.34 Billion by 2028, Driven by Innovations and Rising Demand for Transplants
January 28, 2024 19:49 ET
|
Research and Markets
Dublin, Jan. 28, 2024 (GLOBE NEWSWIRE) -- The "Kidney Transplant Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global interest in the kidney transplant...
American Kidney Fund Announces April 30 as the First Annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day
January 25, 2024 08:50 ET
|
American Kidney Fund
ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day. Building on AKF’s...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 23, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Global Chronic Kidney Disease Market Poised for Growth, Projected to Reach $83.6 Billion by 2030
January 23, 2024 03:08 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
January 11, 2024 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024 08:06 ET
|
ZyVersa Therapeutics
View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024 08:07 ET
|
ZyVersa Therapeutics
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
December 18, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Healthmap Solutions Signs Health Equity Pledge
December 06, 2023 08:00 ET
|
Healthmap Solutions
Kidney population health management company Healthmap Solutions, Inc. signs Health Evolution Forum’s Health Equity Pledge.